Key facts
- Moat Biotechnology’s last known valuation is $56.5M (Dec 2023).
- It has raised $8.2M across 1 recorded rounds; the latest was Later Stage VC ($30K) in Oct 2025.
- Notable investors include Cortado Ventures, Boyd Street Ventures.
- Moat Biotechnology has filed 3 Form Ds with the SEC since 2022, most recently Feb 2023 ($102K sold to 2 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Moat Biotechnology
Funding rounds
1 roundsAbout Moat Biotechnology
Developer of oral vaccines designed to accelerate the treatment of infectious diseases. The company holds an complete patent license for the novel second-generation single-cycle adenovirus vaccine platform to develop intranasal and oral vaccines that can elicit and boost both mucosal and systemic immunity for the treatment of viruses and infectious diseases, enabling patients with significantly advanced treatment over existing and traditional vaccines.
- Sector
- Healthcare
- HQ
- Oklahoma City, OK, United States
- Founded
- 2022
- Ownership
- Privately Held (backing)
Moat Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Moat Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Moat Biotechnology in its N-PORT filings yet. We sweep new filings monthly.